Combihale Ipratropium Bromide 0.5MG/Salbutamol Sulfate 2.5MG

  • Hudson Pharma is the pioneer in Pakistan for introducing COMBIHALE - The only Ipratropium Bromide & Salbutamol Fixed Combination Nebulizing Solution.
  • Combihale (Ipratropium Bromide and Salbutamol) is indicated for the treatment of bronchospasm (airway narrowing) in patients with asthma and chronic obstructive pulmonary disease (COPD) for rapid relief of symptoms, as COMBIHALE provides dual action therapy offering a synergistic response.
  • Each 2.5mL respule contains 0.5mg Ipratropium Bromide and 2.5mg salbutamol sulphate responsible for greater bronchodilation. It is available in a pack of 5 respules.
  • Combihale is intended for nebulization only.

Product Information

Indications

  • For the treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Contraindications

  • Contraindicated in patients with hypertrophic obstructive cardiomyopathy, tachyarrhythmia or a history of hypersensitivity to salbutamol or Ipratropium Bromide.

Adverse Effects

  • Upper respiratory tract infection
  • Nasopharyngitis
  • Cough
  • Bronchitis
  • Headache
  • Dyspnea

Additional Information/ Precautions

  • Discontinue immediately if paradoxical bronchospasm, hypersensitivity or visual disturbances occur. Use with caution in patients with cardiovascular system disorders and narrow angle glaucoma.

Dosage

Children (<12 years) Adults/Adolescents (≥12 years)
Bronchospasm There is no experience of using Ipratropium Bromide and salbutamol for bronchospasms in children under 12 years. 1 single respule every 6 to 8 hours as needed.
Exacerbations of Asthma (acute, severe)* ½-1 respule every 20 minutes for 3 doses, then as needed for up to 3 hours. 1 respule every 20 minutes for 3 doses, then as needed for up to 3 hours.

For prescribing information, Please Click Here